366 related articles for article (PubMed ID: 21195761)
1. The influence of pulmonary surfactant on nanoparticulate drug delivery systems.
Schleh C; Rothen-Rutishauser B; Kreyling WG
Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761
[TBL] [Abstract][Full Text] [Related]
2. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
[TBL] [Abstract][Full Text] [Related]
3. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.
Hadinoto K; Phanapavudhikul P; Kewu Z; Tan RB
Int J Pharm; 2007 Mar; 333(1-2):187-98. PubMed ID: 17084567
[TBL] [Abstract][Full Text] [Related]
4. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
[TBL] [Abstract][Full Text] [Related]
5. Barrier or carrier? Pulmonary surfactant and drug delivery.
Hidalgo A; Cruz A; Pérez-Gil J
Eur J Pharm Biopharm; 2015 Sep; 95(Pt A):117-27. PubMed ID: 25709061
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
7. Formation, characterization, and fate of inhaled drug nanoparticles.
Zhang J; Wu L; Chan HK; Watanabe W
Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
[TBL] [Abstract][Full Text] [Related]
8. Has nanotechnology led to improved therapeutic outcomes?
Bosselmann S; Williams RO
Drug Dev Ind Pharm; 2012 Feb; 38(2):158-70. PubMed ID: 22191583
[TBL] [Abstract][Full Text] [Related]
9. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary drug delivery: medicines for inhalation.
Henning A; Hein S; Schneider M; Bur M; Lehr CM
Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
[TBL] [Abstract][Full Text] [Related]
11. Interaction of nanoparticles with the pulmonary surfactant system.
Schleh C; Hohlfeld JM
Inhal Toxicol; 2009 Jul; 21 Suppl 1():97-103. PubMed ID: 19558240
[TBL] [Abstract][Full Text] [Related]
12. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.
Zhang Y; Zhu J; Tang Y; Chen X; Yang Y
Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model.
Beck-Broichsitter M; Gauss J; Packhaeuser CB; Lahnstein K; Schmehl T; Seeger W; Kissel T; Gessler T
Int J Pharm; 2009 Feb; 367(1-2):169-78. PubMed ID: 18848609
[TBL] [Abstract][Full Text] [Related]
14. Unique benefits of nanotechnology to drug delivery and diagnostics.
McNeil SE
Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949
[TBL] [Abstract][Full Text] [Related]
15. The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles.
Garcia-Mouton C; Hidalgo A; Cruz A; Pérez-Gil J
Eur J Pharm Biopharm; 2019 Nov; 144():230-243. PubMed ID: 31560956
[TBL] [Abstract][Full Text] [Related]
16. Insulin-micro- and nanoparticles for pulmonary delivery.
Klingler C; Müller BW; Steckel H
Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles for direct nose-to-brain delivery of drugs.
Mistry A; Stolnik S; Illum L
Int J Pharm; 2009 Sep; 379(1):146-57. PubMed ID: 19555750
[TBL] [Abstract][Full Text] [Related]
18. Inhaled nanoparticles--a current review.
Yang W; Peters JI; Williams RO
Int J Pharm; 2008 May; 356(1-2):239-47. PubMed ID: 18358652
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for drug delivery to the lungs.
Sung JC; Pulliam BL; Edwards DA
Trends Biotechnol; 2007 Dec; 25(12):563-70. PubMed ID: 17997181
[TBL] [Abstract][Full Text] [Related]
20. Micro- and nanocarrier-mediated lung targeting.
Kurmi BD; Kayat J; Gajbhiye V; Tekade RK; Jain NK
Expert Opin Drug Deliv; 2010 Jul; 7(7):781-94. PubMed ID: 20560777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
